Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study

Atherosclerosis. Supplements
U SchatzS R Bornstein

Abstract

Lipoprotein(a) (Lp(a)) is an independent cardiovascular (CV) risk factor, predisposing to premature and progressive CV events. Lipoproteinapheresis (LA) is the only efficacious therapy for reducing Lp(a). Data comparing the clinical efficacy of LA with respect to reduction of CV events in subjects with elevated Lp(a) versus LDL-C versus both disorders is scarce. We aimed to perform this comparison in a multicenter observational study. 113 LA patients from 8 apheresis centers were included (mean age 56.3 years). They were divided into 3 groups: Group I: Lp(a) < 600 mg/l, LDL-C > 2.6 mmol/l, Group II: Lp(a) > 600 mg/l, LDL-C < 2.6 mmol/l, and Group III: Lp(a) > 600 mg/l, LDL-C > 2.6 mmol/l. CV events were documented 2 years before versus 2 years after LA start. Before start of LA Group II showed the highest CV event rate (p 0.001). Group III had a higher CV event rate than Group I (p 0.03). During LA there was a significant reduction of CV events/patient in all vessel beds (1.22 ± 1.16 versus 0.33 ± 0.75, p < 0.001). The highest CV event rate during LA was seen in coronaries followed by peripheral arteries, cerebrovascular events were least common. Greater CV event reduction rates were achieved in patients with isolated Lp(a) ele...Continue Reading

Citations

Mar 16, 2019·Clinical Research in Cardiology Supplements·Norbert Weiss, Ulrich Julius
Jul 28, 2019·Current Atherosclerosis Reports·Thomas M StulnigClaudia Stefanutti
May 12, 2018·Journal of Cardiovascular Development and Disease·Ulrich Julius
Jul 9, 2020·Journal of Clinical Medicine·Maria Francesca GrecoMassimiliano Ruscica
Sep 19, 2020·Current Atherosclerosis Reports·Sergei N PokrovskyMarat V Ezhov
Mar 7, 2019·Clinical Research in Cardiology Supplements·U JuliusS R Bornstein
Dec 11, 2019·Atherosclerosis. Supplements·Ulrich JuliusStefan R Bornstein
Dec 11, 2019·Atherosclerosis. Supplements·Georgiana-Aura GiurgeaHelmut Sinzinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.